Intra-Cellular depression data has investors feeling good

17 April 2024

Shares in US CNS specialist Intra-Cellular Therapies (Nasdaq: ITCI) closed 23% higher on Tuesday.

This followed the New York firm’s presentation of positive top-line results from Study 501 evaluating lumateperone 42mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).

"A significant step towards our goal of further establishing Caplyta as a first-choice treatment across mood disorders"Lumateperone 42mg - given once daily as adjunctive therapy to antidepressants - met the primary endpoint in Study 501 by demonstrating a statistically-significant and clinically-meaningful reduction in the Montgomery-Åsberg Depression Rating Scale total score compared to placebo at week six.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK